Aperio Group LLC boosted its position in shares of ResMed Inc. (NYSE:RMD) by 11.4% during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 57,911 shares of the medical equipment provider’s stock after buying an additional 5,949 shares during the period. Aperio Group LLC’s holdings in ResMed were worth $4,510,000 at the end of the most recent reporting period.

Several other large investors have also recently made changes to their positions in the stock. Airain ltd purchased a new stake in shares of ResMed during the first quarter worth about $1,242,000. Dai Ichi Life Insurance Company Ltd purchased a new stake in shares of ResMed during the first quarter worth about $205,000. Geode Capital Management LLC raised its stake in shares of ResMed by 5.5% in the first quarter. Geode Capital Management LLC now owns 1,176,810 shares of the medical equipment provider’s stock worth $84,667,000 after buying an additional 61,478 shares in the last quarter. Wealthsource Partners LLC raised its stake in shares of ResMed by 14.5% in the first quarter. Wealthsource Partners LLC now owns 8,230 shares of the medical equipment provider’s stock worth $592,000 after buying an additional 1,045 shares in the last quarter. Finally, American Research & Management Co. raised its stake in shares of ResMed by 3.2% in the first quarter. American Research & Management Co. now owns 11,340 shares of the medical equipment provider’s stock worth $816,000 after buying an additional 350 shares in the last quarter. 60.68% of the stock is owned by hedge funds and other institutional investors.

Shares of ResMed Inc. (NYSE RMD) traded down 0.08% during mid-day trading on Friday, hitting $72.56. 427,178 shares of the stock traded hands. ResMed Inc. has a one year low of $56.59 and a one year high of $79.63. The stock has a 50 day moving average price of $76.52 and a 200-day moving average price of $72.27. The company has a market cap of $10.32 billion, a P/E ratio of 30.23 and a beta of 0.83.

ResMed (NYSE:RMD) last released its quarterly earnings results on Tuesday, August 1st. The medical equipment provider reported $0.77 EPS for the quarter, topping the consensus estimate of $0.75 by $0.02. The firm had revenue of $556.69 million for the quarter, compared to analyst estimates of $557.68 million. ResMed had a return on equity of 21.99% and a net margin of 16.56%. ResMed’s revenue for the quarter was up 7.3% on a year-over-year basis. During the same period in the previous year, the company posted $0.74 EPS. On average, analysts forecast that ResMed Inc. will post $3.03 earnings per share for the current fiscal year.

The business also recently declared a quarterly dividend, which will be paid on Thursday, September 21st. Investors of record on Thursday, August 17th will be given a dividend of $0.35 per share. The ex-dividend date of this dividend is Tuesday, August 15th. This is a positive change from ResMed’s previous quarterly dividend of $0.33. This represents a $1.40 annualized dividend and a yield of 1.93%. ResMed’s payout ratio is 54.77%.

COPYRIGHT VIOLATION NOTICE: “Aperio Group LLC Buys 5,949 Shares of ResMed Inc. (NYSE:RMD)” was reported by TheOlympiaReport and is the sole property of of TheOlympiaReport. If you are accessing this piece of content on another site, it was illegally stolen and reposted in violation of US & international trademark & copyright laws. The original version of this piece of content can be read at https://theolympiareport.com/2017/08/12/aperio-group-llc-has-4-51-million-position-in-resmed-inc-nysermd-updated.html.

RMD has been the subject of a number of analyst reports. BidaskClub raised shares of ResMed from a “buy” rating to a “strong-buy” rating in a report on Saturday, June 17th. Citigroup Inc. cut shares of ResMed from a “buy” rating to a “neutral” rating in a research report on Friday, April 28th. Zacks Investment Research raised shares of ResMed from a “sell” rating to a “hold” rating in a research report on Tuesday, June 20th. Needham & Company LLC reaffirmed a “sell” rating on shares of ResMed in a research report on Wednesday, August 2nd. Finally, Credit Suisse Group cut shares of ResMed from an “outperform” rating to a “neutral” rating in a research report on Wednesday, August 2nd. Four analysts have rated the stock with a sell rating, six have assigned a hold rating and three have assigned a buy rating to the company’s stock. The company currently has an average rating of “Hold” and a consensus price target of $65.63.

In other ResMed news, Director Richard Sulpizio sold 65,887 shares of the company’s stock in a transaction that occurred on Thursday, June 22nd. The stock was sold at an average price of $77.82, for a total value of $5,127,326.34. Following the transaction, the director now directly owns 4,429 shares of the company’s stock, valued at approximately $344,664.78. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, insider Jr. Gregor K. Emmert bought 424,000 shares of the business’s stock in a transaction on Wednesday, June 28th. The stock was acquired at an average cost of $0.06 per share, for a total transaction of $25,440.00. Over the last ninety days, insiders sold 204,650 shares of company stock worth $15,516,845. 1.97% of the stock is currently owned by corporate insiders.

ResMed Company Profile

ResMed Inc is a holding company. The Company is engaged in the development, manufacturing, distribution and marketing of medical devices and cloud-based software applications that diagnose, treat and manage respiratory disorders, including sleep disordered breathing (SDB), chronic obstructive pulmonary disease (COPD), neuromuscular disease and other diseases.

Institutional Ownership by Quarter for ResMed (NYSE:RMD)

Receive News & Ratings for ResMed Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ResMed Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.